Imunon, Inc.
IMNNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Imunon, Inc. focuses on Biotechnology services and products. Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. Valued at $6.9M, IMNN is a micro-cap name in its sector. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Market Cap
$6.9M
Beta
2.00
P/E (TTM)
—
P/E (Fwd)
-0.70
EPS (TTM)
$-3.95
EPS (Fwd)
$-1.77
ROE
-429.7%
ROA
-78.0%
Cash
$6.9M
Total Debt
$7.8M
Free CF
-$9.5M
52W Change
-74.4%
Annual Financials
Cash vs Debt
Where IMNN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMNN finished 50.99% below its 150-day moving average ($2.02) and 58.05% below its 200-day moving average ($2.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMNN overbought or oversold?
At the October 20, 2026 close, IMNN's RSI(14) was 15.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $6.9M in cash, though total debt stands at $7.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$9.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -429.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $500K (2022) to $0 (2025), a 100% decline worth watching.
A beta of 2.00 means IMNN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IMNN.